Prostate Cancer

Daniel R. Saltzstein, MD, describes steps Urology San Antonio has taken toward creation of a comprehensive urologic care practice, including establishment of a bone health clinic and an advanced prostate cancer clinic.

James Mohler, MD, from Roswell Park Cancer Institute, discusses androgen-deprivation therapy, a standard treatment for men with metastatic prostate cancer.

Daniel P. Petrylak, MD, from the Smilow Cancer Center, discusses the recent approval and future role of enzalutamide for patients with prostate cancer.

Novel formulations of specialty drugs have shifted the treatment of patients taking oncologic and biologic agents from infusion centers to the doctor's office.

In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.

Abiraterone acetate significantly improved overall survival with positive responses seen in several subgroups of patients with metastatic castration-resistant prostate cancer.

A quick glance at a recent study examining the renal cell carcinoma immunotherapy AGS-003 and the FDA approval of a new noninvasive prostate health index test.

Dr. Daniel Petrylak, from the Smilow Cancer Center at Yale-New Haven, Explains the Correlation Between Immune Response to Sipuleucel-T and Survival.

Targeted focal therapy offers some men with localized prostate cancer a solution between active surveillance and definitive treatment with surgery and/or radiation.

The FDA approved enzalutamide for use in patients with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel and hormonal therapy.

Dr. James Mohler, from Roswell Park Cancer Institute, Discusses the Need for Intermediate Endpoints for Early Stage Prostate Cancer Trials.

The FDA announced that Priority Review has been granted to abiraterone acetate for certain advanced prostate cancer cases based on positive data presented at the ASCO annual meeting.

Researchers have determined that patients who received sipuleucel-T (Provenge, Dendreon) developed immune parameters that correlate to improved overall survival, giving researchers a better understanding of how the immunotherapy works at a cellular level to improve survival.

The novel drug enzalutamide (formerly MDV3100) significantly improved overall survival in men with metastatic castrate-resistant prostate cancer (mCRPC).

Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses the Unblinding of the COU-AA-302 Trial